38027014|t|Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).
38027014|a|Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and zoledronic acid (ZA), compare their association strengths, and explore potential applications to provide clinical reference. Methods: We collected data from FAERS from January 2004 to November 2022 and mined AE signals for Dmab and ZA using ROR values. We compared signal intensity for same AEs and investigated off-label use. We also examined their AEs in adjuvant therapy for breast and prostate cancer. Results: 154,735 reports of primary suspect drugs were analyzed in the FAERS database (Dmab: 117,857; ZA: 36,878). Dmab and ZA had 333 and 1,379 AE signals, with 189 overlaps. The AEs of Dmab included death (ROR:3.478), osteonecrosis of jaw (ROR:53.025), back pain (ROR:2.432), tooth disorder (ROR:16.18), bone pain (ROR:6.523). For ZA, the AEs included osteonecrosis (ROR:104.866), death (ROR: 3.645), pain (ROR:3.963), osteonecrosis of jaw (ROR: 91.744), tooth extraction (ROR: 142.143). Among overlap signals, Dmab showed higher strength in exostosis of the jaw (ROR: 182.66 vs. 5.769), atypical fractures (ROR: 55.589 vs. 9.123), and atypical femur fractures (ROR:49.824 vs. 4.968). And ZA exhibited stronger associations in abscess jaw (ROR: 84.119 vs. 11.12), gingival ulceration (ROR: 74.125 vs. 4.827), increased bone formation (ROR: 69.344 vs. 3.218). Additionally, we identified 528 off-label uses for Dmab and 206 for ZA, with Dmab mainly used in prostate cancer (1.04%), breast cancer (1.03%), and arthritis (0.42%), while ZA in breast cancer (3.21%), prostate cancer (2.48%), and neoplasm malignant (0.52%). For Dmab in breast cancer treatment, AEs included death (11.6%), disease progression (3.3%), and neutropenia (2.7%), while for ZA included death (19.8%), emotional disorder (12.9%), osteomyelitis (11.7%). For prostate cancer treatment, Dmab`s AEs were death (8.9%), prostate cancer metastatic (1.6%), renal impairment (1.7%), while ZA`s included death (34.4%), general physical health deterioration (19.9%), and hemoglobin decreased (18.9%). Conclusion: Our analysis of FAERS database provided postmarketing surveillance data and revealed different strengths of reported AE signals between Dmab and ZA in some of their common AEs. It's also worth noting that both drugs have potential off-label applications, which could introduce new AEs. This highlights the necessity for safety monitoring when using Dmab and ZA off-label.
38027014	15	28	adverse event	Disease	MESH:D064420
38027014	41	50	denosumab	Chemical	MESH:D000069448
38027014	55	70	zoledronic acid	Chemical	MESH:D000077211
38027014	90	103	adverse event	Disease	MESH:D064420
38027014	193	202	denosumab	Chemical	MESH:D000069448
38027014	204	208	Dmab	Chemical	MESH:D000069448
38027014	214	229	zoledronic acid	Chemical	MESH:D000077211
38027014	231	233	ZA	Chemical	MESH:D000077211
38027014	437	441	Dmab	Chemical	MESH:D000069448
38027014	446	448	ZA	Chemical	MESH:D000077211
38027014	592	618	breast and prostate cancer	Disease	MESH:D001943
38027014	707	711	Dmab	Chemical	MESH:D000069448
38027014	722	724	ZA	Chemical	MESH:D000077211
38027014	735	739	Dmab	Chemical	MESH:D000069448
38027014	744	746	ZA	Chemical	MESH:D000077211
38027014	807	811	Dmab	Chemical	MESH:D000069448
38027014	821	826	death	Disease	MESH:D003643
38027014	840	860	osteonecrosis of jaw	Disease	MESH:D059266
38027014	875	884	back pain	Disease	MESH:D001416
38027014	898	912	tooth disorder	Disease	MESH:D014076
38027014	926	935	bone pain	Disease	MESH:D010146
38027014	953	955	ZA	Chemical	MESH:D000077211
38027014	974	987	osteonecrosis	Disease	MESH:D010020
38027014	1003	1008	death	Disease	MESH:D003643
38027014	1023	1027	pain	Disease	MESH:D010146
38027014	1041	1061	osteonecrosis of jaw	Disease	MESH:D059266
38027014	1077	1093	tooth extraction	Disease	MESH:D014076
38027014	1133	1137	Dmab	Chemical	MESH:D000069448
38027014	1164	1184	exostosis of the jaw	Disease	MESH:D005096
38027014	1219	1228	fractures	Disease	MESH:D050723
38027014	1267	1282	femur fractures	Disease	MESH:D000092524
38027014	1311	1313	ZA	Chemical	MESH:D000077211
38027014	1349	1360	abscess jaw	Disease	MESH:D007571
38027014	1386	1405	gingival ulceration	Disease	MESH:D005892
38027014	1441	1455	bone formation	Disease	MESH:D058426
38027014	1532	1536	Dmab	Chemical	MESH:D000069448
38027014	1549	1551	ZA	Chemical	MESH:D000077211
38027014	1558	1562	Dmab	Chemical	MESH:D000069448
38027014	1578	1593	prostate cancer	Disease	MESH:D011471
38027014	1603	1616	breast cancer	Disease	MESH:D001943
38027014	1630	1639	arthritis	Disease	MESH:D001168
38027014	1655	1657	ZA	Chemical	MESH:D000077211
38027014	1661	1674	breast cancer	Disease	MESH:D001943
38027014	1684	1699	prostate cancer	Disease	MESH:D011471
38027014	1713	1731	neoplasm malignant	Disease	MESH:D009369
38027014	1745	1749	Dmab	Chemical	MESH:D000069448
38027014	1753	1766	breast cancer	Disease	MESH:D001943
38027014	1791	1796	death	Disease	MESH:D003643
38027014	1838	1849	neutropenia	Disease	MESH:D009503
38027014	1868	1870	ZA	Chemical	MESH:D000077211
38027014	1880	1885	death	Disease	MESH:D003643
38027014	1895	1913	emotional disorder	Disease	MESH:D009358
38027014	1923	1936	osteomyelitis	Disease	MESH:D010019
38027014	1950	1965	prostate cancer	Disease	MESH:D011471
38027014	1977	1981	Dmab	Chemical	MESH:D000069448
38027014	1993	1998	death	Disease	MESH:D003643
38027014	2007	2022	prostate cancer	Disease	MESH:D011471
38027014	2042	2058	renal impairment	Disease	MESH:D007674
38027014	2073	2075	ZA	Chemical	MESH:D000077211
38027014	2087	2092	death	Disease	MESH:D003643
38027014	2331	2335	Dmab	Chemical	MESH:D000069448
38027014	2340	2342	ZA	Chemical	MESH:D000077211
38027014	2544	2548	Dmab	Chemical	MESH:D000069448
38027014	2553	2555	ZA	Chemical	MESH:D000077211
38027014	Association	MESH:D000077211	MESH:D009369
38027014	Positive_Correlation	MESH:D000069448	MESH:D001416
38027014	Negative_Correlation	MESH:D000077211	MESH:D010146
38027014	Negative_Correlation	MESH:D000077211	MESH:D001943
38027014	Association	MESH:D000077211	MESH:D010019
38027014	Positive_Correlation	MESH:D000069448	MESH:D000092524
38027014	Positive_Correlation	MESH:D000077211	MESH:D005892
38027014	Negative_Correlation	MESH:D000069448	MESH:D001168
38027014	Positive_Correlation	MESH:D000077211	MESH:D009503
38027014	Negative_Correlation	MESH:D000077211	MESH:D011471
38027014	Positive_Correlation	MESH:D000077211	MESH:D007571
38027014	Association	MESH:D000077211	MESH:D014076
38027014	Positive_Correlation	MESH:D000069448	MESH:D010146
38027014	Association	MESH:D000077211	MESH:D009358
38027014	Positive_Correlation	MESH:D000069448	MESH:D005096
38027014	Positive_Correlation	MESH:D000077211	MESH:D059266
38027014	Positive_Correlation	MESH:D000077211	MESH:D007674
38027014	Comparison	MESH:D000069448	MESH:D000077211
38027014	Positive_Correlation	MESH:D000069448	MESH:D009503
38027014	Positive_Correlation	MESH:D000069448	MESH:D050723
38027014	Positive_Correlation	MESH:D000069448	MESH:D007674
38027014	Positive_Correlation	MESH:D000077211	MESH:D010020
38027014	Negative_Correlation	MESH:D000077211	MESH:D001168
38027014	Negative_Correlation	MESH:D000069448	MESH:D011471
38027014	Positive_Correlation	MESH:D000077211	MESH:D058426

